Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016015 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT01016015: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01016015 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 178 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016015, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth by blocking the ability of tumor cells to grow and spread. Giving temsirolimus with cixutumumab may be an effective treatment for soft tissue or bone sarcoma.
Primary Outcome
From study entry until recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death or date of last contact, assessed at 12 weeks
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Temsirolimus
- BIOLOGICAL Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01016015 record still lists
NCT01016015 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01016015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01016015 about?
NCT01016015 is a clinical study titled "Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma". This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibod...
What is the current status of trial NCT01016015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2009-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01016015?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temsirolimus (DRUG), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01016015?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01016015's enrollment target sits among peer trials
178 391st of 2000 higher than 1,607 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia